Real‐life experience in switching to new extended half‐life products at European haemophilia centres
- 16 August 2019
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 25 (6) , 946-952
Abstract
The concept of replacement therapy in haemophilia is changing significantly thanks to the switch from standard products to extended half‐life products. These novel drugs are showing beneficial effects overcoming current prophylaxis limitations by reducing the infusion frequency, maintaining a higher trough level to ensure a lower risk of bleeding, and making treatment significantly less distressing to patients by improving the quality of life. Real‐life data on the efficacy of novel drugs and their impact on routine management of haemophilia A and B patients are still limited. This manuscript reports the results of a European survey conducted by the European Association for Haemophilia and Allied Disorders (EAHAD) at the beginning of 2018 on the clinical management of patients using extended half‐life recombinant FVIII and FIX fusion products, since at the time of the survey none of the PEGylated products were available yet. We report data on the efficacy of these novel drugs by 33 European haemophilia centres that have already switched to extended half‐life fusion products, showing a significant reduction in the number of infusions and a satisfactory trough levels in the clinical care of haemophilia patients, with a greater impact for haemophilia B.Keywords
This publication has 29 references indexed in Scilit:
- PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved DrugsJournal of Pharmaceutical Sciences, 2016
- New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting ProteinsDrugs, 2015
- PEGylated BiopharmaceuticalsToxicologic Pathology, 2015
- Longer‐acting clotting factor concentrates for hemophiliaJournal of Thrombosis and Haemostasis, 2015
- Role of enhanced half‐life factor VIII and IX in the treatment of haemophiliaBritish Journal of Haematology, 2015
- Treatment of Hemophilia in the Near FutureSeminars in Thrombosis and Hemostasis, 2015
- Reply to: The importance and challenge of pediatric trials of hemophilia drugsNature Medicine, 2014
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia ABlood, 2014
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- The Hemophilias — From Royal Genes to Gene TherapyNew England Journal of Medicine, 2001